Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds GENE.
No tracked institution reports a position in GENE as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-12-14 | 1-for-5reverse |
| 2019-08-15 | 1-for-4reverse |
| 2015-01-20 | 1-for-5reverse |
No one on the platform has traded GENE yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$OTLK $NVS $GENE $REGN https://www.globenewswire.com/news-release/2026/05/26/3300933/0/en/outlook-therapeutics-wins-appeal-following-formal-dispute-resolution-process-for-ons-5010-lytenava-bevacizumab-vikg.html The FDA concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD). As a result, Outlook Therapeutics expects to resubmit the ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) in June 2026. Yesssssss!
View on StockTwits ↗$GENE once upon a time you made me a lot of money. Now we part ways
View on StockTwits ↗$GENE Ever get bullied??? Trading stocks?? Me too!!! Well 🖕🩳🖕🔥🔥🔥🩳🖕🩳🔥
View on StockTwits ↗$GENE I used to dream of GENE, but it was all a pipe.....
View on StockTwits ↗$IXHL semi-good news for stateside baggies soon they'll only dilute Australians like $GENE
View on StockTwits ↗The New York Times and Amazon Strike AI Content Deal: Retail’s Yet To React $NYT $AMZN $GENE $RSPC https://stocktwits.com/news/equity/markets/new-york-times-and-amazon-strike-ai-content-deal/ch0AswDRbtM
View on StockTwits ↗$GENE i remember making $16k on this stock in one day - RIP
View on StockTwits ↗$GENE is there any news on this one since delisting?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.